经皮肺动脉瓣介入治疗的研究现状  

Research status of percutaneous pulmonary valve treatment

作　　者：李锐韬 李怡坚 冯沅[2] LI Ruitao;LI Yijian;FENG Yuan(West China School of Medicine,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Department of Cardiology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西临床医学院,成都610041 [2]四川大学华西医院心脏内科,成都610041

出　　处：《华西医学》2022年第9期1293-1298,共6页West China Medical Journal

基　　金：国家自然科学基金(82001899);四川大学华西医院专职博士后研发基金(2019HXBH078)。

摘　　要：经皮肺动脉瓣介入诊疗是当今研究的热点,主要包括了经皮肺动脉瓣球囊扩张成形术及经皮肺动脉瓣植入。经皮肺动脉瓣球囊扩张成形术是治疗肺动脉瓣狭窄首选的治疗方案。经皮肺动脉瓣植入术的主要适应证为肺动脉瓣反流和/或梗阻。经皮肺动脉瓣植入术是当前的研究热点,手术指征在不断完善,手术器械在不断研发,但相较于外科肺动脉瓣置换仍有局限。该文就经皮肺动脉瓣介入诊疗,尤其是经皮肺动脉瓣植入术的研究现状进行综述。Nowadays,percutaneous pulmonary valve treatment is a hot topic in valvular heart disease,consisting of percutaneous balloon pulmonary valvuloplasty and percutaneous pulmonary valve implantation(PPVI).The percutaneous balloon pulmonary valvuloplasty is the prime intervention of pulmonary valve stenosis.The main indication of PPVI is pulmonary valve regurgitation and/or obstruction.PPVI is still the research focus,with the improvement of surgical indications and the development of surgical devices.However,compared with surgical pulmonary valve replacement,it still has limitations.This article reviews the treatment progress of percutaneous pulmonary valve treatment,especially PPVI.

关 键 词：经皮肺动脉瓣介入治疗 经皮肺动脉瓣球囊扩张成形术 经皮肺动脉瓣植入 

分 类 号：R543.2[医药卫生—心血管疾病]